• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
OB

CDC Guidance for Non-Pregnant Patients and Available Diagnostic Tests for Zika Virus

image_pdfFavoriteLoadingFavorite

Zika virus disease is a nationally notifiable condition:

Healthcare providers should report suspected Zika virus disease cases to their state, local, or territorial health department to facilitate diagnosis and mitigate risk of local transmission. State, local, and territorial health departments should report laboratory-confirmed and probable cases to CDC.

CLINICAL ACTIONS:

The following is a summary of CDC testing protocols.  For detailed protocols and information, the CDC resource pages can be found in the Learn More – Primary Sources section below

Testing Guidance for Non-Pregnant patients

Symptomatic individuals with possible exposure to Zika virus

  • CDC defines ‘exposure’ to Zika virus as travel or residency in an area of active Zika virus transmission or sexual intercourse without a condom with a parter who has lived in or traveled to such an area
  • Concurrent testing of serum and urine by Zika virus ribonucleic acid (RNA) nucleic acid testing (NAT) and Zika virus and dengue virus IgM testing of serum is recommended
  • NAT testing is dependent on the timing of specimen collection
    • NAT testing should be performed on specimens collected <14 days after symptom onset
      • NAT testing is not recommended on specimens collected ≥ 14 days after symptom onset
    • Zika virus and dengue virus IgM serology testing should be performed on NAT negative samples collected <14 days after onset of symptoms or on samples collected ≥14 days after onset of symptoms

SYNOPSIS:

Testing for Zika virus is available using molecular and serological assays. Typical symptoms include acute onset of fever, with maculopapular rash, arthralgia, myalgia, headache, conjunctivitis. Differential diagnosis of such symptoms is broad and include group A strep, rubella, measles and other viral diseases. Therefore, to identify those at risk for Zika virus, it is essential to take a travel and sexual history of all patients presenting with the above symptoms and to stay current with CDC updates as to high Zika virus transmission areas.

KEY POINTS:

Tests for Zika virus include the following

Molecular Testing: Triplex Real-time RT-PCR Assay (rRT-PCR)

  • A molecular test designed to detect Zika virus, Dengue virus and Chikungunya virus RNA
  • FDA is currently allowing its use under an Emergency Use Athoriziation
  • RNA can be detected in the acute phase, and up to 14 days post symptoms in urine
  • If clinically indicated, amniocentesis and CSF specimens may be tested alongside patient-matched serum sample

Antibody Detection Methods: Zika virus IgM

  • Antibody testing not required if there is a a positive rRT-PCR result
  • Due to cross reactivity, symptomatic individuals should be tested for anti-Zika and anti-Dengue IgM and where clinically relevant, anti-chikungunya IgM

PRNT (Plaque Reduction Neutralization Test) to confirm antibodies

  • Works by quantifying the antibodies that neutralize the virus
  • Positive or equivocal IgM results must be confirmed with an antibody neutralization assay to rule out false positives (previous and not recent infection)
  • Not necessary with positive rRT-PCR which is definitive
  • Test is performed by the CDC or CDC approved lab
  • PRNT may not be able to provide definitive determination of the specific virus causing the recent infection

Learn More – Primary Sources:

CDC: Zika Virus For Healthcare Providers

CDC: Areas with Risk of  Zika

ACOG Zika Tool Kit 

 

image_pdfFavoriteLoadingFavorite

< Previous
All OB Posts
Next >

Related ObG Topics:

New CDC Interim Guidance on Infants with Possible Zika & Perinatal Review (Oct 2017)
Practical obstetrics info for your women's healthcare practice
Microcephaly – Beyond the Zika Virus
Zika Virus Disease: How to Counsel Your Patient About Prevention
Zika virus: transmission, symptoms and management
CDC Guidance on Zika and Pregnancy

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site